Loading
A phase 2 trial of Paclitaxel / nab-paclitaxel in ovarian cancer, run by Shanghai Jiaolian Drug Research and Development Co., Ltd, now recruiting.
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. is a phase 2 interventional study registered as NCT06434610 by Shanghai Jiaolian Drug Research and Development Co., Ltd, with 90 participants planned, started 2024-07-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: B013, Paclitaxel, Placebo. Conditions listed: Platinum-resistant Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer.